Beloo Mirakhur

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 2.9K citations

Oncology, Braf-mutated Metastatic Melanoma, Melanoma +6

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

Christine H. Chung, Beloo Mirakhur, Emily Chan et al. · New England Journal of Medicine · 2008 · 1.5K citations · Full text

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

Andrea Wang‐Gillam, Richard Hubner, Jens T. Siveke et al. · European Journal of Cancer · 2019 · 299 citations · Full text

MAGRIT: The Largest-Ever Phase III Lung Cancer Trial Aims to Establish a Novel Tumor-Specific Approach to Therapy

Preeta Tyagi, Beloo Mirakhur · Clinical Lung Cancer · 2009 · 174 citations

Medicine, Immune Checkpoint Inhibitor, Novel Tumor-specific Approach +6

High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses.

F. Bellot, Wouter H. Moolenaar, Richard Kris et al. · The Journal of Cell Biology · 1990 · 147 citations · Full text

Human Growth, Immunology, Cell Growth +19